The libraries were sequenced on Illumina NovaSeq 6000 Systems and 125 bp/150 bp paired-end reads were generated. == Differential expression genes analysis and functional enrichment analysis == Statistical analysis of DEGs was performed using the DEseq2 R package (1.16.1). anti-MDA5 titers and type I IFN scores (r = 0.50,P< 0.001). Contemporaneous anti-MDA5 titers revealed to be significantly higher in the group with ultra-high type I IFN scores (vs.high group,P= 0.027;vs.low group,P< 0.001). Longitudinal assessment of type I IFN scores and anti-MDA5 titers, including pre- and post-treatment changes at initial diagnosis and dynamic changes Neratinib (HKI-272) during treatment, presented an asynchrony between the two parameters in response to treatment. == Conclusion == Anti-MDA5 antibody titers correlated with type I IFN signature in patients with MDA5+ DM and they both changed dynamically but not synchronously over the course of treatment. Keywords:dermatomyositis, interstitial lung disease, melanoma differentiation-associated gene 5, type I interferon, autoantibody == Introduction == Anti-melanoma differentiation-associated gene 5 antibody positive dermatomyositis (MDA5+ DM), a subtype of idiopathic inflammatory myopathies (IIMs), is usually distinguished by a high risk of rapidly progressive interstitial lung disease (RP-ILD), scarcely clinical evidence of myopathy, and typical skin lesions. In the past two decades, the terminology of MDA5+ DM had been gradually transformed from clinically amyopathic dermatomyositis (CADM) and subsequently is usually defined by a centerpiece of serologic anti-MDA5 antibodies (1,2). MDA5+ DM has a poor prognosis related to the presence of RP-ILD. An appalling proportion of patients fail to survive the first 6 or 12 months of disease onset (3,4), but interestingly, the relapse rate is lower in surviving patients (4). MDA5, as the autoantigen target of anti-MDA5 antibody (primitively known as anti-CADM-140), is usually one of three cytosolic retinoic acid-inducible gene I (RIG-I)-like receptors (RLRs), RIG-I, MDA5, and LGP2. Besides, MDA5, encoded by IFN-inducible Rabbit polyclonal to WWOX gene (IFIH1 in human), is usually a key protein sensor to recognize dsRNA produced during viral infections. After binding to long-chain dsRNA, MDA5 interacts with the adapter MAVS, followed by a phosphorylation cascade that enables signaling leading to the production of IFNs and finally induces the expression of ISGs (5). In addition, type I interferon further induces MDA5 at the transcriptional level and positive feedback amplifies the interferon response (6). While type I interferon (IFN) signature has emerged as a potential factor linked to the pathogenesis of myositis, especially the MDA5 subtype. Current studies have revealed excessive type I IFN signals in peripheral blood, skin, and even muscle tissue of MDA5+ DM patients (albeit known with moderate or no myopathy) (711). Interestingly, clinical features of severe coronavirus disease 2019 (COVID-19) are strikingly similar to MDA5+ DM, including chest radiology, devastating cytokine storm, and even treatment approach (1214). MDA5 has been proposed to be a major sensor for lung cell recognition of SARS-CoV-2 contamination and governs the IFN induction in response to SARS-CoV-2 in lung epithelial cells (15,16). Besides, anti-MDA5 antibodies are prevalent in COVID-19 patients and higher titer is related to severe disease and adverse outcomes (17). Likewise, cytokine levels, as well as antibody titers are dynamic in MDA5+ DM, and anti-MDA5 titer at diagnosis predict disease duration and correlate with disease relapse, prognosis and treatment response (4,1216). Similarities of both diseases may bring a deeper insight on the Neratinib (HKI-272) role of viruses Neratinib (HKI-272) and type I IFN in disease mechanism. Therefore, we have speculated that it is the anti-MDA5 antibody, produced by viral contamination or the release of RNA from impaired or aberrant cells, that may bind to MDA5 pattern recognition receptor to produce pathogenic effect, driving the production of type I interferon signaling consequently leading to inflammation and tissue damage. Here, we investigate the transcriptomic scenery of differences between MDA5+ patients with high-titer at the onset of disease and those recovered to normal low-titer after intensive treatment. Subsequent dynamic assessment of antibody titers with ensuing interferon response was performed to explore the fluctuating patterns. Findings on the conversation between anti-MDA5 antibody and type I IFN signature may provide new clues for the immunopathogenesis and potential therapeutic targets in MDA5+ DM. == Materials and methods == == Patients == The retrospective study was conducted at the First Affiliated Hospital of Zhengzhou University (China) from January Neratinib (HKI-272) 2021 to December 2021. All MDA5+ DM patients were over 18 years old and fulfilled the 2017 EULAR/ACR Classification Criteria for Idiopathic Inflammatory Myopathies (18). Patients with overlapping disease, juvenile onset or coexistent malignancy were excluded from this study. First, we collected peripheral blood mononuclear cells (PBMCs) for RNA sequencing (RNA-seq) from a total of 13 MDA5+ DM patients (including 8 with high-titer antibody at disease onset or relapse and 5.